ArticleBMC cancer2026
Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCachexia is a multifactorial syndrome associated with impaired physiologic reserve and adverse outcomes in advanced NSCLC. Its relationship with early toxicity and survival during EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy remains insufficiently characterized. We evaluated the impact of baseline cachexia on toxicity and clinical outcomes in patients with EGFR-mutated stage III–IV NSCLC treated with EGFR-TKIs. PATIENTS AND
methodsIn this retrospective cohort, 247 consecutive patients treated with EGFR-TKIs were included. Cachexia was defined using the Fearon international consensus criteria. Hematologic and selected non-hematologic adverse events were recorded during the first four months of therapy. Associations with hematologic toxicity were assessed using logistic regression, and progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier methods and Cox regression.
resultsBaseline cachexia was present in 91 patients (37%). Cachectic patients more frequently had KPS <90 (44% vs 27%) and liver metastases (19% vs 5.8%). Overall hematologic toxicity was higher among cachectic versus non-cachectic patients (85.7% vs 69.9%), driven mainly by anemia (40% vs 21%) and lymphopenia (74% vs 56%). Cachexia independently predicted hematologic toxicity (adjusted OR 2.26, 95% CI 1.15–4.68) and worse OS (adjusted HR 1.65, 95% CI 1.07–2.57); median OS was 37.22 months in cachectic patients versus 45.80 months in non-cachectic patients.
conclusionsBaseline cachexia was associated with a higher burden of early hematologic toxicity and independently worse OS in EGFR-mutated advanced NSCLC treated with EGFR-TKIs. Routine baseline identification may help prioritize early supportive care and closer monitoring during the initial months of therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.